Based on this knowledge, we provide a roadmap for the rational clinical development of targeted and immunotherapeutic strategies that are specific to UTUC but also potentially applicable to other tumor types harboring FGFR3-activating molecular alterations. The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.